SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Biocept Inc. – ‘10-Q’ for 9/30/22 – ‘EXCEL’

On:  Monday, 11/21/22, at 4:10pm ET   ·   For:  9/30/22   ·   Accession #:  1564590-22-38094   ·   File #:  1-36284

Previous ‘10-Q’:  ‘10-Q’ on 11/10/22 for 6/30/22   ·   Next:  ‘10-Q/A’ on 4/17/23 for 9/30/22   ·   Latest:  ‘10-Q’ on 8/14/23 for 6/30/23   ·   22 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/21/22  Biocept Inc.                      10-Q        9/30/22   60:7.7M                                   ActiveDisclosure/FA

Quarterly Report   —   Form 10-Q

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML   1.01M 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     25K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     25K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     20K 
 5: EX-32.2     Certification -- §906 - SOA'02                      HTML     20K 
11: R1          Document and Entity Information                     HTML     71K 
12: R2          Condensed Balance Sheets                            HTML    114K 
13: R3          Condensed Balance Sheets (Parenthetical)            HTML     36K 
14: R4          Condensed Statements of Operations (Unaudited)      HTML     96K 
15: R5          Condensed Statements of Stockholders' Equity        HTML     82K 
16: R6          Condensed Statements of Cash Flows (Unaudited)      HTML    103K 
17: R7          The Company, Business Activities and Basis of       HTML    135K 
                Presentation                                                     
18: R8          Liquidity                                           HTML     23K 
19: R9          Sales of Equity Securities                          HTML     27K 
20: R10         Balance Sheet Details                               HTML    108K 
21: R11         Payor Liability                                     HTML     21K 
22: R12         Leases                                              HTML    123K 
23: R13         Stock-Based Compensation                            HTML    111K 
24: R14         Common Stock Warrants Outstanding                   HTML     61K 
25: R15         Net Loss per Common Share                           HTML     45K 
26: R16         Commitments and Contingencies                       HTML     22K 
27: R17         Related Party Transactions                          HTML     23K 
28: R18         Subsequent Events                                   HTML     21K 
29: R19         The Company, Business Activities and Basis of       HTML    143K 
                Presentation (Policies)                                          
30: R20         The Company, Business Activities and Basis of       HTML    106K 
                Presentation (Tables)                                            
31: R21         Balance Sheet Details (Tables)                      HTML    108K 
32: R22         Leases (Tables)                                     HTML    121K 
33: R23         Stock-Based Compensation (Tables)                   HTML    115K 
34: R24         Common Stock Warrants Outstanding (Tables)          HTML     61K 
35: R25         Net Loss per Common Share (Tables)                  HTML     43K 
36: R26         The Company, Business Activities and Basis of       HTML     45K 
                Presentation - Additional Information (Detail)                   
37: R27         The Company, Business Activities and Basis of       HTML     37K 
                Presentation - Composition of Net Revenues                       
                Recognized Disaggregated by Source (Detail)                      
38: R28         The Company, Business Activities and Basis of       HTML     37K 
                Presentation - Summary of Third-Party Payers That                
                Represent More Than 10% of Total Net Revenues and                
                Total Accounts Receivable (Detail)                               
39: R29         Liquidity - Additional Information (Detail)         HTML     44K 
40: R30         Sales of Equity Securities - Additional             HTML     63K 
                Information (Detail)                                             
41: R31         Balance Sheet Details - Schedule of Fixed Assets    HTML     70K 
                and Accrued Liabilities (Detail)                                 
42: R32         Leases - Additional Information (Detail)            HTML     89K 
43: R33         Leases - Schedule of Lease Expense (Detail)         HTML     28K 
44: R34         Leases - Schedule of Represents Maturities of       HTML     57K 
                Operating and Finance Lease Liabilities (Detail)                 
45: R35         Leases - Supplemental Cash Flow Information         HTML     25K 
                Related to Operating and Finance Leases (Detail)                 
46: R36         Stock-Based Compensation - Additional Information   HTML     43K 
                (Detail)                                                         
47: R37         Stock-Based Compensation - Summary of Stock Option  HTML     43K 
                Activity (Detail)                                                
48: R38         Stock-Based Compensation - Assumptions Used for     HTML     35K 
                Determining Fair Value of Stock Options Under                    
                Black-Scholes Pricing Model (Detail)                             
49: R39         Stock-Based Compensation - Effects of Stock-Based   HTML     33K 
                Compensation Related to Equity Awards to Employees               
                and Nonemployees on Condensed Statement of                       
                Operations and Comprehensive Loss (Detail)                       
50: R40         Common Stock Warrants Outstanding - Summary of      HTML     28K 
                Equity-Classified Common Stock Warrant Activity                  
                (Detail)                                                         
51: R41         Common Stock Warrants Outstanding - Additional      HTML     26K 
                Information (Detail)                                             
52: R42         Net Loss per Common Share - Additional Information  HTML     25K 
                (Detail)                                                         
53: R43         Net Loss per Common Share - Schedule of             HTML     31K 
                Anti-Dilutive Securities Excluded from                           
                Computations of Diluted Weighted-Average Shares                  
                (Detail)                                                         
54: R44         Commitments and Contingencies - Additional          HTML     22K 
                Information (Detail)                                             
55: R45         Related Party Transactions - Additional             HTML     26K 
                Information (Detail)                                             
58: XML         IDEA XML File -- Filing Summary                      XML    106K 
56: XML         XBRL Instance -- bioc-10q_20220930_htm               XML   1.71M 
57: EXCEL       IDEA Workbook of Financial Reports                  XLSX     75K 
 7: EX-101.CAL  XBRL Calculations -- bioc-20220930_cal               XML    158K 
 8: EX-101.DEF  XBRL Definitions -- bioc-20220930_def                XML    324K 
 9: EX-101.LAB  XBRL Labels -- bioc-20220930_lab                     XML   1.02M 
10: EX-101.PRE  XBRL Presentations -- bioc-20220930_pre              XML    687K 
 6: EX-101.SCH  XBRL Schema -- bioc-20220930                         XSD    154K 
59: JSON        XBRL Instance as JSON Data -- MetaLinks              308±   457K 
60: ZIP         XBRL Zipped Folder -- 0001564590-22-038094-xbrl      Zip    221K 


‘EXCEL’   —   IDEA Workbook of Financial Reports


This is an IDEA Workbook.

        Download this Microsoft® Excel® .xlsx workbook


22 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/24/22  Biocept Inc.                      8-K:5,9     3/22/22   11:148K                                   Donnelley … Solutions/FA
11/16/20  Biocept Inc.                      10-Q        9/30/20   70:8.7M                                   ActiveDisclosure/FA
 9/04/20  Biocept Inc.                      8-K:3,5,9   9/03/20    2:62K                                    ActiveDisclosure/FA
 1/09/20  Biocept Inc.                      8-K:1,3,9   1/09/20    3:284K                                   ActiveDisclosure/FA
12/11/19  Biocept Inc.                      8-K:8,9    12/09/19    4:290K                                   ActiveDisclosure/FA
12/06/19  Biocept Inc.                      S-1/A                  3:816K                                   ActiveDisclosure/FA
 5/29/19  Biocept Inc.                      8-K:1,3,9   5/28/19    3:273K                                   ActiveDisclosure/FA
 3/18/19  Biocept Inc.                      8-K:1,3,8,9 3/15/19    6:670K                                   ActiveDisclosure/FA
11/28/18  Biocept Inc.                      S-1                    4:827K                                   ActiveDisclosure/FA
 9/24/18  Biocept Inc.                      8-K:1,3,8,9 9/20/18    7:830K                                   ActiveDisclosure/FA
 8/13/18  Biocept Inc.                      8-K:3,5,8,9 8/09/18    3:463K                                   ActiveDisclosure/FA
 7/11/18  Biocept Inc.                      S-1/A                 15:3.6M                                   Donnelley … Solutions/FA
 7/06/18  Biocept Inc.                      8-K:3,5,9   7/06/18    2:57K                                    ActiveDisclosure/FA
 1/30/18  Biocept Inc.                      8-K:8,9     1/30/18    2:161K                                   ActiveDisclosure/FA
 1/22/18  Biocept Inc.                      S-1/A                 86:9.1M                                   Donnelley … Solutions/FA
 9/29/17  Biocept Inc.                      8-K:5,9     9/27/17    2:49K                                    ActiveDisclosure/FA
 8/10/17  Biocept Inc.                      8-K:1,3,9   8/09/17    3:333K                                   ActiveDisclosure/FA
 3/30/17  Biocept Inc.                      8-K:1,3,8,9 3/28/17    7:627K                                   ActiveDisclosure/FA
 9/29/16  Biocept Inc.                      8-K:5,8,9   9/27/16    3:319K                                   ActiveDisclosure/FA
 5/06/14  Biocept Inc.                      8-K:1,2,3,9 4/30/14    3:366K                                   Donnelley … Solutions/FA
 2/14/14  Biocept Inc.                      8-K:1,3,5,8 2/10/14    3:368K                                   Donnelley … Solutions/FA
 9/23/13  Biocept Inc.                      S-1¶                  71:6.2M                                   Donnelley … Solutions/FA
Top
Filing Submission 0001564590-22-038094   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Tue., May 14, 12:51:48.2pm ET